across multiple We and Thank success. you, quarter a for delivered Good strong thank joining you of third today. everyone, afternoon, operator. measures us
momentum. ahead Aspira our pre-pandemic the of is over weathering Women's projected pandemic the on levels significantly timing. increased in quarter, prior volumes the believe building and rebounding and revenue the effectively storm Health We to of September Our
test lastly medical lives, recovery, to improved team. We and executive our significant solid have made sequentially, board, added and to delivered price additions volume covered our
position our in our advance pipeline XXXX. and product financial strengthen continue We to
have our our and well media campaign compared and early We strengthen awareness digital of and disparity also test advantages risk to as of identity, racial increased CAXXX. of to brand its a launched as detection
We investment analysts. bank from received recently also coverage two
each We progress, University turn. and Medical to have are Sandra prestigious bring board, our our on in Hospital. expand appointment with Starting at made Senior upon very and of appointment we these Chief to team, Dr. efforts and the of President Vice Thomas we'll recently this to proud board, Jefferson Brooks, MD, a announced Officer our
as will an Brooks advising Given disparities, Dr. she be into our in drive brings overall in of awareness racial would of invaluable of the woman's important the which board also the we suite as a equity, status, feel OVA company note pathway. as resource on to company. as products longstanding health I health this female driving adoption health research majority care interest well to and appointment
is additional several also School That mission for cure. of early This envision. part totally medicines all the Co-Director Advisor. Co-Chief have Dr. announcements, Oncology ovarian focused resonates combating Medicine we Medical to company's of Elena cancers. Aspira's serving women. We as Chief initiative cancer initiative detection She are with of program Yale Yale University on of Ratner, is the discovery our at as Gynecologic reproductive adding
sales her of organization and one comprised the as the Operating promotion Chief researcher Officer. Chief entire a executive the to who the Professor well clinical laboratory. will have operations, Gynecologic Kalie an translational role have of overall as Spokeswoman, addition Dr. lead addition Powis ovarian journey, Associate At Scientific and well. level, operating to and is and In commercial the Officer, marketing, patient. cancer Dr. advisory an storytelling of and we two Northrop ethnically our and meet, whose Kalie, have Dr. serve the announcements, educate Dr. Altwerger, we avid testimonial With and Ratner, for the is at IT including she'll management clinical patient diverse be the of is Zagger lastly, Powis. Chief survivor, be how to of and we an patient coordination as background patient Dr. Gary Medicine, Oncology board. Diane responsible as added cornerstone advocacy, And Lesley responsible is added we Yale for and
to build the our make momentum team. organization, and board senior to we these As additions scale an as strategic time and it's leadership
we growth. by our Aspira significantly an now help QX moving company a the per lows led third perspective, of pre-COVID quarter September comparing We of will women day operational on on XXXX I a additions these experienced and to From a is for am now ended and February to of XX% the XXXX our women QX. V-curve on at women propel for versus somewhat update. levels, volumes basis.
the to quarter increased the sequentially volume third the Our quarter, XXXX. volume and second XX% of is of equivalent from
price XX% one unit increased sequentially as OVAXplus Our well, average by quarter. second the of versus plus
being efforts platform pay-off COVID-XX a and of integrated Regarding this prospect adoption deals. deals networks penetrate accelerated and strategy engage of OB/GYN the decentralization and our groups. delivery strategy, internalizing and our our More lead overall into the care super pathway our has the to super products. our respective of about to these partners our some have continue integrate should believe on decentralized large of time pandemic the significant continue to groups front. large arrangement the products technology. That said, are come The to finalize we institutions help and will to excited slowed These ultimately
announced are Cross Blue of Shield October participating front, Blue that On the Georgia. Anthem we with in providers payer we
million approximately considerable. across additional XX% state. now of in covered the Georgia, X.X have For the lives an members We estimated is which
million X, covered As approximately of November we the lives in XXXX, XXX have U.S.
illustrates on and the the rate. of retention impact total ordering quarter, XX% care, with with for clearly opportunity the the being of we portfolio. technology physicians consistent X,XXX and OVAX, technology This with has customers overall of terms the customers, stickiness ordered expanded In submissions growth those have the repeat QX our patient
the physicians of In addition, quarter, the the tests compared number up prior second and in is ordered year to of number practice XX% XX% per increased quarter. third ordering
surveyed We also that needs to determine majority immediately determine of customers OVAX customers, surgery. who using who XXX who these surgery saw or the were recently postpone can
of believe practice. In invaluable were benefit specimens repeat high be visit. fact, post to touched Thus survey, based sense of a or improvement high environment. of urgency on this OVAX the of the risk these may XX% symptomatic, ER triage new in patients needed We per that an this low it and be seen or rate with
drive overall a OVAX of make of major standard and care. one adoption adoption. We believe goal is in the number lack obstacle Our to awareness is
and ovarian and level, Number board diagnosis. importance health call in three, effective in expedite of cancer clinical of short-term to magnify illuminate We are awareness at community and devastating disparity coupled virtual academic and winning woman's one, strategically driving awareness commercial two, KLO advanced by patient the the and its the strategy our the at lifecycle Number ways. demonstrated newly academic long-term following for entire and non-virtual nature a of the designed the September an earlier executive our more brand, with participation increased trial our as the addition. lift focus pathways together of to and impact impact and Number health clinical and our enrolment KLO level.
interviews Media interview a Virtual in as major advocate. our area. television and quarter. your We had in Dr. social the May all to print in featured our XX I a television As well you campaign media through by up tour witness illustrated campaign. the Montana outlets. conducted The by launched hope campaign digital We radio as have first outlets Hazel, was awareness Ratner, picked Elena that opportunity that patient or third and
shared The cost driven cancer cancer. disparity including quite awareness is emphasizing ovarian while million a campaign subject is level and a power and interest general, We Bloomberg we placements, like we and early driving and be to Ferris result Associated media of in Pharma, ethnic significant, a the As risk consider had of total detection. earned successful XXX to of XXX few a this in Press, media ovarian name are impressions.
environment. continue of a have mix the to we XXXX sales As emphasis field. marketing to maximize in into continuing our inside transform those virtual as a higher anticipate and face-to-face on do commercial reported and personnel organization reps the We of previously, virtual perform in effectiveness
on approach addition, moving progress of studies. digital in construction and In will our marketing, be optimization, expansion and pipeline update. now deep Despite innovation non-virtual to social clinical be search and and will clinical initiatives I made to tremendous across engine we America pandemic, leveraging media, North virtual our the our participation and champion have site awareness. team the product on wide drive website enhancement
products to And OvaInherit, assessment OVAXPlus. With during mass assessment, are in our our clinical ENDOCHECK that enlarging risk at increase are premenopausal a surgery was benign execution woman's of risk a including high-risk adult our XX life over lastly, also geographic experience comprised years enrollment cancer impact we a with to in starting on is to pandemic. and a young risk cancer cancer patient broad mode which of We cycle for entire studies portfolio prior ensure the creating genetics, ovarian monitoring OVANEX. hereditary ovarian to
start addition, sites going front research with ethnic am in also to new on our disparity are queue. we I In with the doubling down on now ENDOCHECK.
leading in product about U.S. diagnosis still expected is the reach excited way roughly as the to total tool. and million. it's $X This used We market of only $X a surgical an are Today very to this confirm million addressable to product. diagnostic is biopsy a endometriosis primary a
on blinded a endometrial Elagolix in to test years addition enrolled endometriosis samples is other which robust and very and the may endometriosis, pharmaceutical moderate a equal placebo-controlled biopsy. double contains develop was is women greater per large biopsy an a it but patient treatment initially Not a specimen. to we need of women, unmet clinical as severe a masses. to severe the from trial with with with is are and to large developed Phase based Our sometimes is or These associated with extremely Based on similar cost There only with which agreement on endometriosis trials formed a X nine to Elagolix diabetic. to and two multicenter product diagnose diagnosed end have access number X women sensitivity This us does than average performance, endometriosis the Biobank, multiple mass surgically management who treated to impact for high type initial to as to goal that surgeries. pain. of is both liquid take benign endometriosis. surgical the their from specificity allowed pain symptoms seven mass, algorithm AbbVie, is moderate pelvic a associated
and development, our product the We are about samples this market bring to from acquisition to AbbVie ENDOCHECK this product excited will swiftly. these believe strengthen very of for ability
an we previously As the for discussed, are end submission preparing device designation year. by FDA of the breakthrough
has the also validate to women reproductive collecting thereby cohorts endometriosis, academic potential liquid treatment the and are AbbVie to of speed essential it with outcomes to collaboration their detection this product. A the as addition with help to notable improving without finalizing improving a a enriched ultimately In treatment we disease. surgery, life for is of begin from further consortium endometriosis biopsy debilitating specimen, and the quality
mask who need year actively who not XX% everyone we with Adnexal patients is designed masses and when Choices I Index two surgery that There low XXX invasive mass, the were low Multivariant Keep of in of surgery demonstrated is the have pelvic specifically status us risk. Surgical charts clinically. no of assessing mind OVAX Risk Scores, pelvic in market is now there titled, on were risk with of clinicians no though immediate the surgery OVANEX that to management risk cancers are comfortable and OVAX, performed. per would had is with These expected transvaginal times October, benign published results an followed XXX even individual it scores, is third-generation Physician test, a trial Assay our consenting update reviews, to with women were the in times risk and CAXXX, research pelvic which with cancer of In and independent launched In IRB patients. of we we patients were besides which already on Masses. four masses. seven is Due on-boarding to performed opinion, address OVANEX. Surgery to on low June, product market competitive pandemic, is our a was had a have medical to current have the in to A XX of no Second, prospective goal assessment challenges, there ultrasound. and XX% face sites. our currently to clinical total Low we ovarian results. monitored other three sites, with with CAXXX monitor Women increased is paper approved the like known to and for recruitment granted Referral patient the five of
genetically We Number cohorts a the for with mass. who symptomatic study. malignancy not for are one with mass. that will better and monitoring number manage is predisposed tool help who test patients of candidates are And were without will are and three understand Number who three found. are a incidentally this are patients asymptomatic, be mass who We looking at provide a with this patients and clinicians to a believe overtime the to two are patients surgery. risk those pelvic masses
now product clinical phases designed our risk end assessment. to OVAInherit target are foundation solution on for OVAX as track triage two a surgical as genetic a symptomatic two, a be OVA This are I is separate real to risk research study at And a is well symptomatic for monitoring early And is specifically Keep we our which solution mind in with product commercial are performed projecting coupling moving as pelvic predisposition. this XXXX. continue the a OVAInherit. multi-site genomic of a with established with sites at study We time Number are reserved number institutions. in am OVANEX. that genetics early to the It is across being mass. next one coupled protein that This product of detection a our also high-risk testing with launch XXXX the solution. of five provides to on designed is current and who women being women cohorts.
molecular combining as gynaecological to behind a established specific adding the will name the is study of with also will is academic OVAXXX research a of that OVAInherit will The targets to proteins diagnostic which key cancers. ultrasound, of cancer, demonstrating and a prestigious test. test of study centre a female planned. tumor just This defined DNA as prevalence cancer. with tissue define free, specific announced an with algorithms XXX assist We soon. be provide degree be based outperform which explore view development and standard identify ovarian current cell type study high targets and that with cell genomic will early drivers of is the a gynaecologic Foundational care, We of precise accuracy measurement our cancer starting believe is the cancer detection coupled CAXXX a transvaginal at of early
now We will beyond expanding into OVAInherit to ethnic genomic in key I the support will disparity OVAXPlus. also leaders with be of community partnering the research the with thought move development our product. development on product several
during timelines study increasing pandemic with a Especially Center our all we site We are initial a are core at study institutions Women's recognized by quality, research to Einstein expanding inequality recruitment Medical more more to studies. risk this disparity ovarian at portfolio in to increase recruitment mining goals bringing come. lead two clinical as Health healthcare our is our we decided Aspire Again, time Philadelphia, charge product during across more when the from partner continue to to in becoming cancer and COVID, as forefront. values the our to assessment meet healthcare
standard across ovarian greater performing a of products, ethnicities. and with as CAXXX virus cancer, on-suite accuracy disease this of place to is goal of a one all number Our care precision for with
the OVAX turn care. studies of our the to like Bob? call this results. compared outside previously standard for truly for review CAXXX change to I women to Caucasian and Bob published to would upon of expand financial populations of is study now our over to validate goal across Our two as
